Exchange: NASDAQ·Updated 07:30 PM EST
ARCT logo

ARCT Arcturus Therapeutics Holdings Inc

$7.55
$0.15
(1.97%)
Today
Closed $7.45
$0.10
(1.34%)
After Hours
Reported EarningsNov 5
Mkt Cap$214.73M
Vol601,998.00

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
44

Bearish Sentiment

How do you feel about ARCT?

birdflustocks
$ARCT "However, we do have a technology and capabilities that can enable key players in the oncology space. With the recent acquisition of myNEO, we now have capabilities of neoantigen design, and we have clearly a differentiated saRNA platform that is better at engaging T cells, for example, and proven mRNA delivery and manufacturing. For these reasons, of course, we're always open to enabling key players in oncology (...)" $BNTX
14
Nganlm
$ARCT Part 2 on ARCT-032 Other programs were unable to proceed with home administration and patients had to go to the clinic daily for administration. ARCT-032 can be administered at home. Some patients have already successfully completed the 12-week study. No severe significant safety events, no triggers. In another conversation, Alan highlighted that if there is going to be an ascertainable clinical signal, that 12 weeks should be sufficient using clinically relevant measures such as changes in FEV1, LCI, 2 quality of life measures and HRCT…. Personally, I think “No” company in history has come this far with inhaled mRNA therapeutic for Cystic fibrosis Class 1 patients. This is a potential breakthrough! Note the recent termination of Moderna $MRNA and Vertex $VRTX program VX522, Sionna had a failed CF readout and drugmaker Boehringer Ingelheim ended a trial of a gene therapy for CF.
14
Choice79
$ARCT when you include the shares just issued Arct has approx 31mm shares outstanding. At a price of $7.64 that’s a market cap of $237MM. At the end of September the company had $184.8mm in cash. Add the $50MM that’s $234.8mm in cash. So the stock is now trading at cash. No value at all for any programs, patents, technology or potential.
9
Nganlm
$ARCT From Google AI, “By proving that LUNAR 2.0™ can safely navigate liver tissue at ultra-low doses, they potentially have unlocked the key to the entire human metabolic engine. The same architecture they are testing for OTC and PKU can seamlessly scale into Obesity, MASH, and Cardiovascular care—representing a total addressable market that easily exceeds $100 billion globally. Gout was probably Arcturus' first warning shot to the industry that they are no longer just a "rare disease company".” So, from the above, the platforms and technologies of Arcturus can be used to develop many other therapies, not just rare diseases but a host of other applications as well. Very excited about the future of ARCT. Just my own thoughts. Two events this week, Guggenheim 9 Nov and Stifel conference 11 Nov.
10
Dr_Feel_Good
$ARCT solid earnings report. I feel rest assured more knowing the balance sheet showing cash runway out to year end 2028. Remain long and have it on my list to dca below $14. Ideally like to get cost avg around $12.50 if we can maintain above $10.
10
Yooman
$ARCT Sooner or later, this will be a minimum 100USD Stock. 266.04 M is just a joke. What the investor needs here, is patience. Nice WE to all the contributors here. Thank you.
9
Choice79
$ARCT arkg is buying more. Two days in a row. They’ve added nearly 40,000 shares. They have a big position already so really good news that they are adding.
9
2PacalypseNow4Life
$ARCT truth is, ppl, they dont have to make a decision Just yet, and i understand their Approach. They have Time and so do i. Im here to contribute. Fight The CF!!!!!
7
Nganlm
$ARCT Part 1 on ARCT-032 One of the biggest takeaways from the earnings call was from Alan Cohen, the Chief Medical Officer of ARCT. He mentioned that recently Vertex $VRTX stopped advancing their own messenger RNA LNP program due largely to safety concerns. And what they were aware was that in Vertex $VRTX study, in order to continue to conduct the trial, they needed things like systemic steroids on a daily basis in a population that has pancreatic insufficiency already and problems with blood glucose levels. Vertex was using moderate dose inhaled long-acting bronchodilators and inhaled corticosteroids on top of that. For Arcturus, Alan said they didn’t need to do that, they were just using a bronchodilator which most of these patients use daily as part of their standard of care for airway clearance and Arcturus only have them doing that for first 2 weeks and the patients can stop if they want to.
7
King316
$ARCT Roth Capital lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $40 from $41 and keeps a Buy rating on the shares. The firm notes Meiji Seika Pharma invested $50M in Arcturus, adding cash to support OTC deficiency and cystic fibrosis development.
6
King316
$ARCT ​I have to apologize, but even though the stock market doesn't appreciate this move, I think it's a very good deal for me as a long-term investor.
6
mebanks
$ARCT ; definitely worth a watch "$50 Million Strategic Investment in Arcturus at an 80% Premium Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform"
5
2PacalypseNow4Life
$ARCT mc $243mil. $180sth mil in cash. no debt. Arcalis share worth approx 300mil. Technology/platform worth approx , lets say 800mil at least. first in The World samrna vaccine. am i Missing sth?:D
5
2PacalypseNow4Life
$ARCT i believe some good news gonna be announced. they always keepin IT quiet. maybe going into phase 3 with arct032 maybe partnership, maybe both. :)
5
Rayvio_News_Filter
$ARCT · $MEJHF 💰 Arcturus Therapeutics Holdings Inc. sold 2,466,395 common shares to Meiji Seika Pharma Co., Ltd. for $50.0 million at an 80% premium to the 30-trading-day average closing price through November 11, 2026. Market-relevant event
4
StocktwitsEarnings
$ARCT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.26 up 46.94% YoY • Reported revenue of $18.3M up 6.71% YoY
4
birdflustocks
$ARCT During the recent $BNTX earnings call the previously proposed mRNA spin-off was described as "optional" in a prepared statement. Detailed plans were supposed to be announced at the end of Q2 2026 but there was only silence. For my thesis this means that the BioNTech mRNA spin-off is very unlikely to prevent a collaboration with or buyout of Arcturus Therapeutics.
4
Papav
$ARCT bullish on the stock, but has anyone ever got a reply from investor relations when you sent them an email?
3
wahoowa95
$ARCT Phase 2 full data from Cohort 4 are planned for presentation in Q2 2027. 🤣 Delaying the results wont save your company Joe
3
wahoowa96
$ARCT Meiji Seika is using self-amplifying mRNA to solid tumor therapeutics. It seems Lunar 2.0 is wanted by Meiji Seika. Interesting if Arct-154 sa-mRNA vaccines with LUNAR 2.0 can do wonders for cancer vaccines without another combination therapy option...
2

Advertisement|Remove ads.